We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
InSite Vision to Advance new Ocular Anti-Inflammatory Candidate
Product News

InSite Vision to Advance new Ocular Anti-Inflammatory Candidate

InSite Vision to Advance new Ocular Anti-Inflammatory Candidate
Product News

InSite Vision to Advance new Ocular Anti-Inflammatory Candidate


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "InSite Vision to Advance new Ocular Anti-Inflammatory Candidate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

InSite Vision Incorporated announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

InSite Vision formulated a lower concentration of bromfenac with its proprietary DuraSite® technology to create a proprietary therapeutic product. InSite Vision intends to advance ISV-303 into clinical studies pending the completion of Investigational New Drug-enabling toxicology studies in the first half of 2010.

“ISV-303 uses a lower concentration of an approved product and combines it with a commercially-proven technology to create a promising therapeutic that we believe will offer significant safety, efficacy and dosing advantages,” said Kamran Hosseini, M.D., Ph.D., Chief Medical Officer and Vice President, Clinical Affairs.

“Our DuraSite platform offers a number of therapeutic advantages, as has been demonstrated in two commercial products, AzaSite and Besivance, which leverage this technology. In preclinical studies, ISV-303 appears to offer compelling benefits that we hope will translate into an improved, easy-to-use eye drop to alleviate the pain and swelling associated with cataract surgery. We look forward to advancing this new development candidate into clinical trials next year.”
Advertisement